Rapid Micro Biosystems, Inc.

Equities

RPID

US75340L1044

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
0.9456 USD -0.46% Intraday chart for Rapid Micro Biosystems, Inc. +6.25% +27.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the First Quarter, Second Quarter, Third Quarter and Fourth Quarter of 2024 CI
Transcript : Rapid Micro Biosystems, Inc., Q4 2023 Earnings Call, Mar 01, 2024
Rapid Micro Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Reports Q4 Revenue $6.3M MT
Rapid Micro Biosystems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Rapid Micro Biosystems, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM
Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System CI
Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 CI
Rapid Micro Biosystems Shares Rise After Samsung Biologics Partnership DJ
US Equity Futures Narrowly Mixed Pre-Bell as Traders Refrain From Making Big Bets Ahead of Friday's Jobs Report MT
Top Premarket Gainers MT
Transcript : Rapid Micro Biosystems, Inc., Q3 2023 Earnings Call, Nov 03, 2023
Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Posts Q3 Revenue $6.1M MT
Rapid Micro Biosystems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023 CI
Transcript : Rapid Micro Biosystems, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 07:30 AM
Transcript : Rapid Micro Biosystems, Inc., Q2 2023 Earnings Call, Aug 04, 2023
Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Reports Q2 Revenue $5M, vs. Street Est of $4.15M MT
Rapid Micro Biosystems, Inc. Reaffirms Earnings Guidance for the Full Year 2023 CI
Rapid Micro Biosystems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Rapid Micro Biosystems Names Kirk Malloy as Board Chair MT
Rapid Micro Biosystems, Inc. Appoints of Kirk Malloy as Chair of Its Board of Directors CI
Transcript : Rapid Micro Biosystems, Inc., Q1 2023 Earnings Call, May 05, 2023
Rapid Micro Biosystems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Rapid Micro Biosystems, Inc.
More charts
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9456 USD
Average target price
5.25 USD
Spread / Average Target
+455.20%
Consensus
  1. Stock Market
  2. Equities
  3. RPID Stock
  4. News Rapid Micro Biosystems, Inc.
  5. Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Reports Q4 Revenue $6.3M